This study provides valuable insights into how auditory stimuli influence the temporal dynamics of visual perception by modulating brain rhythms (oscillations) in the alpha band. The authors present ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Cornellians for Israel launched a petition against the selection of Kehlani as this year’s Slope Day headliner, stating that the use of “her platform to publicly call for the ‘intifada ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

Formula E drivers Norman Nato and Nyck De Vries are currently in Italy for the second round of the 2025 FIA World Endurance Championship (WEC). They participated in the 6 Hours of Imola Qualifying ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.